We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cboe Global Secures 25-Year SPX Rights: Can Volume Boost Growth?
Read MoreHide Full Article
Key Takeaways
Cboe extends exclusive SPX options licensing rights for 25 years through 2051.
SPX options volume hit 970.6 million contracts in 2025, with daily volume up 25% year over year.
CBOE may pursue new SPX products, while revised royalty terms in 2027 could increase costs.
Cboe Global Markets, Inc. (CBOE - Free Report) is strengthening its core derivatives business by extending its exclusive licensing agreement with S&P Dow Jones Indices for another 25 years, through 2051. The agreement allows Cboe to continue offering trading in S&P 500 Index (SPX) options, one of its most important products.
The long-term extension is important for CBOE because SPX options generate significant trading activity across its derivatives business. SPX options recorded a record 970.6 million contracts in 2025, with average daily volume of 3.9 million contracts, up 25% year over year. Higher trading volumes can support Cboe's transaction and clearing-related revenues.
Cboe has also expanded the SPX product suite with new expirations, structures and products, helping attract both institutional and retail investors. The company can use the extended agreement to continue developing the franchise and benefit from growing demand for tools that provide exposure to U.S. equities.
The agreement could also support future innovation, as Cboe and S&P DJI may explore products such as tokenized options contracts. However, CBOE remains dependent on trading activity and market conditions. The company also expects revised royalty terms to begin in 2027, which could increase costs.
Overall, the extension secures CBOE’s exclusive access to a key derivatives franchise and provides a long-term platform for volume and product growth. Sustained SPX activity, new product launches and potential innovations could support transaction-based revenue growth and strengthen Cboe’s earnings over time.
What About Its Peers?
CME Group, Inc. (CME - Free Report) is expanding its S&P 500 options franchise with smaller, financially settled Micro E-mini S&P 500 options and Monday-through-Friday expirations. Its E-mini S&P 500 options also posted 1.3 million contracts in average daily volume in the second quarter of 2026, up 7% year over year. The move targets growing demand for flexible and accessible index exposure.
Nasdaq, Inc. (NDAQ - Free Report) continues to strengthen its index derivatives franchise through its NDX options offering daily, weekly, monthly and long-term expirations as well as a broader index-product ecosystem. NDX options volume increased 24% year over year in the second quarter of 2026, reflecting strong demand for index-based derivatives.
CBOE’s Price Performance
CBOE stock has gained 14.5% in a year against the industry’s decrease of 8.3%.
Image Source: Zacks Investment Research
CBOE’s Valuation
The stock is undervalued compared with its industry. It is currently trading at a forward price-to-earnings multiple of 18.72X, lower than the industry average of 19.35X.
Image Source: Zacks Investment Research
Cboe Global’s Growth Projections
The Zacks Consensus Estimate for 2026 revenues indicates a 15.9% year-over-year increase, while that for earnings suggests a 29.2% year-over-year decline.
The consensus estimate for 2027 revenues indicates a 2.7% year-over-year increase, while that for earnings suggests an increase of 5.7% year-over-year.
The consensus estimate for 2026 and 2027 earnings has remained unchanged in the past 30 days.
View the Zacks #1 Rank List
Image: Bigstock
Cboe Global Secures 25-Year SPX Rights: Can Volume Boost Growth?
Key Takeaways
Cboe Global Markets, Inc. (CBOE - Free Report) is strengthening its core derivatives business by extending its exclusive licensing agreement with S&P Dow Jones Indices for another 25 years, through 2051. The agreement allows Cboe to continue offering trading in S&P 500 Index (SPX) options, one of its most important products.
The long-term extension is important for CBOE because SPX options generate significant trading activity across its derivatives business. SPX options recorded a record 970.6 million contracts in 2025, with average daily volume of 3.9 million contracts, up 25% year over year. Higher trading volumes can support Cboe's transaction and clearing-related revenues.
Cboe has also expanded the SPX product suite with new expirations, structures and products, helping attract both institutional and retail investors. The company can use the extended agreement to continue developing the franchise and benefit from growing demand for tools that provide exposure to U.S. equities.
The agreement could also support future innovation, as Cboe and S&P DJI may explore products such as tokenized options contracts. However, CBOE remains dependent on trading activity and market conditions. The company also expects revised royalty terms to begin in 2027, which could increase costs.
Overall, the extension secures CBOE’s exclusive access to a key derivatives franchise and provides a long-term platform for volume and product growth. Sustained SPX activity, new product launches and potential innovations could support transaction-based revenue growth and strengthen Cboe’s earnings over time.
What About Its Peers?
CME Group, Inc. (CME - Free Report) is expanding its S&P 500 options franchise with smaller, financially settled Micro E-mini S&P 500 options and Monday-through-Friday expirations. Its E-mini S&P 500 options also posted 1.3 million contracts in average daily volume in the second quarter of 2026, up 7% year over year. The move targets growing demand for flexible and accessible index exposure.
Nasdaq, Inc. (NDAQ - Free Report) continues to strengthen its index derivatives franchise through its NDX options offering daily, weekly, monthly and long-term expirations as well as a broader index-product ecosystem. NDX options volume increased 24% year over year in the second quarter of 2026, reflecting strong demand for index-based derivatives.
CBOE’s Price Performance
CBOE stock has gained 14.5% in a year against the industry’s decrease of 8.3%.
Image Source: Zacks Investment Research
CBOE’s Valuation
The stock is undervalued compared with its industry. It is currently trading at a forward price-to-earnings multiple of 18.72X, lower than the industry average of 19.35X.
Image Source: Zacks Investment Research
Cboe Global’s Growth Projections
The Zacks Consensus Estimate for 2026 revenues indicates a 15.9% year-over-year increase, while that for earnings suggests a 29.2% year-over-year decline.
The consensus estimate for 2027 revenues indicates a 2.7% year-over-year increase, while that for earnings suggests an increase of 5.7% year-over-year.
The consensus estimate for 2026 and 2027 earnings has remained unchanged in the past 30 days.
Image Source: Zacks Investment Research
CBOE carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.